

**From:** Sweeney, Colleen [<mailto:Colleen.Sweeney@fda.hhs.gov>]  
**Sent:** Wednesday, January 25, 2017 8:44 PM  
**To:** Margaretten, Nadine  
**Cc:** Steele, Matthew; Khurana, Taruna  
**Subject:** Re: Information Request regarding

Dear Dr. Margaretten:

As discussed today, we note that your Pharmacovigilance Action Plan for Specific Safety Concerns makes reference to a proposed Post Marketing Study entitled, "Post-Market Claims and EMR Based Study of Serious Allergic Reactions and Eosinophilic Esophagitis in Marketed Use of MK-8237 in the United States." This study is analogous to, and intends to use the existing database currently utilized for post marketing studies of GRASTEK and RAWITEK.

Please explicitly state if this is a Post Marketing Commitment Study. If so, please indicate if you intend to submit further information including a timeline for protocol submission, study completion, and study report submission.

Please submit this information as an amendment to STN 125592/0.

Thank you.

*Captain Colleen Sweeney R.N., M.S., USPHS*

*Division of Vaccines & Related Product Applications  
Office of Vaccines Research & Review  
Center for Biologics Evaluation & Research  
US Food & Drug Administration  
10903 New Hampshire Ave  
Silver Spring, MD 20993-0002.  
Tel: +1 301 796 2640  
E-Fax: +1 301 402 0004; Fax: +1 301 827 3075  
E. Mail: [colleen.sweeney@fda.hhs.gov](mailto:colleen.sweeney@fda.hhs.gov)*

**THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to addressee, you are hereby notified that any review, disclosure, dissemination, copying or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify the sender by e-mail or phone.**